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Capsule: 
Background: TG2 is a multifunctional matrix protein and crosslinking enzyme. 
Results: Identification and mutation of its heparan sulphate (HS) binding site blocks matrix deposition of 
TG2 as do inhibitors of syndecan shedding. 
Conclusion: Coordinated binding to cell surface heparan sulphates facilitates TG2 cell surface trafficking 
and deposition into the ECM. 
Significance: Blocking heparan sulphate binding provides an avenue for regulating the enzyme’s 
pathological roles. 
 
ABSTRACT 
Tissue transglutaminase (TG2) is a multifunctional 
Ca
2+ 
activated protein crosslinking enzyme 
secreted into the extracellular matrix (ECM), 
where it is involved in wound healing and 
scarring, tissue fibrosis, celiac disease and 
metastatic cancer. Extracellular TG2 can also 
facilitate cell adhesion important in wound healing 
through a non-transamidating mechanism via its 
association with fibronectin (FN), heparan 
sulphates (HS) and integrins. Regulating the 
mechanism how TG2 is translocated into the ECM 
therefore provides a strategy for modulating these 
physiological and pathological functions of the 
enzyme. Here, through molecular modelling and 
mutagenesis we have identified the HS binding 
site of TG2 
202
KFLKNAGRDCSRRSSPVYVGR
222
. We 
demonstrate the requirement of this binding site 
for translocation of TG2 into the ECM through a 
mechanism involving cell surface shedding of HS. 
By synthesizing a peptide 
NPKFLKNAGRDCSRRSS corresponding to the 
HS binding site within TG2, we also demonstrate 
how this mimicking peptide can in isolation 
compensate the RGD-induced loss of cell adhesion 
on FN via binding to syndecan-4, leading to 
activation of PKCα, pFAK-397 and ERK1/2 and 
the subsequent formation of focal adhesions and 
actin cytoskeleton organization. A novel 
regulatory mechanism for TG2 translocation into 
the extracellular compartment that depends upon 
TG2 conformation and the binding of HS is 
proposed. 
 
Abbreviations: TG2, Tissue transglutaminase; 
ECM, Extracellular matrix; FN, Fibronectin; 
HSPG, Heparan sulphate proteoglycans; HS, 
Heparan sulphate; MMPs, Matrix 
metalloproteinases; ERK1/2, Extracellular-signal 
regulated kinase1/2; HOB, Human osteoblasts; 
MEF, mouse embryonic fibroblast; gplTG, Guinea 
pig liver TG; tetracycline-inducible, tet-inducible; 
NS, Non-silencing; PMA, α-phorbol-12, 13-
didecanoate; PKCα, Protein kinase C α; FAK, 
focal adhesion kinase; CHO-K1, Chinese hamster 
ovary-K1; DMEM, Dulbecco’s modified Eagle’s 
medium; FBS, foetal bovine serum; α-Tbl,α-
Tubulin. 
 
INTRODUCTION 
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Over-expression of the Ca
2+
-activated tissue 
transglutaminase (TG2) is closely related to a wide 
range of pathological processes, such as wound 
healing and scarring, fibrosis, celiac disease 
multiple sclerosis and tumour metastasis (1,2). 
Under stress, cells over-express TG2, leading to 
enhanced externalization of the enzyme and the 
increased deposition of TG2 into the extracellular 
matrix (ECM).  A huge amount of effort has been 
devoted to investigating the mechanism of TG2 
secretion, but how it reaches the cell surface and is 
then translocated into the ECM is still unknown. 
Evidence suggests that TG2 is externalized via an 
unconventional secretion pathway, which may 
involve endosome binding (3) and association with 
the cell surface receptors and/or the ECM protein 
fibronectin (FN) (4). Once externalized, the 
enzyme can be deposited into the ECM where it 
forms a hetero-complex with FN and facilitates 
cell adhesion via an RGD-independent pathway, 
which during wound healing and matrix turnover 
can rescue RGD peptide-induced anoikis and 
subsequent loss of FN deposition through a 
syndecan-4/2 and α5β1 integrin signalling 
pathway (5,6). However, in many pathological 
conditions the continuous deposition of TG2 into 
the matrix results in increased protein crosslinking 
leading to the onset of and progression of tissue 
fibrosis and scarring, celiac disease, tumour 
metastases and multiple sclerosis (1,7). Hence 
modulating the mechanism of TG2 translocation 
into the ECM provides an important basis for 
developing therapeutic strategies that are able to 
regulate its physiological and pathological 
functions. 
Interestingly, cell surface heparan sulphate 
proteoglycans (HSPG), for which TG2 has a high 
affinity binding for, are also shed from the cell 
surface and can deposited into the matrix where, 
like TG2, they are associated with a number of 
similar physiological and pathological conditions 
such as bone growth and development (8), wound 
healing and scarring (9), tumour progression (10) 
and angiogenesis (11). The HSPG family is 
composed of four major syndecans ― syndecans 
1-4, of which syndecan-1 and syndecan-4 are 
major resource for shedding into the ECM. By 
activation of cell surface matrix 
metalloproteinases (MMPs), in particular MMP-9 
the HS loaded syndecan ectodomain can be 
cleaved and in turn deposited into ECM (12). The 
aim of this study was firstly to identify the HS 
binding site within the TG2 molecule. To 
demonstrate the importance of this binding site in 
the translocation of TG2 into the ECM and to 
elucidate the mechanism(s) involved. Finally using 
a mimicking peptide resembling the HS binding 
domain on TG2 demonstrate directly the 
importance of this binding site in triggering 
syndecan-4-mediated intracellular signalling 
pathways that rescue cells from the stress-related 
RGD peptide-induced loss of cell adhesion. 
 
EXPERIMENTAL PROCEDURES 
Mammalian cell culture 
Cell lines used in this study include human kidney 
epithelial cells HEK 293T/17 (ATCC CRL-11268) 
and mouse embryo fibroblasts NIH 3T3 (ATCC 
CRL-11268), Chinese hamster ovary cells CHO 
K1 (ATCC CCL-61) and the heparan sulphate 
deficient CHO-K1 derivative pgsD-677 (ATCC 
CRL-2244) (HS-mutant CHO), which were 
obtained from the American Type Culture 
Collection (ATCC, USA). Additionally, human 
osteoblasts (HOB) were kindly provided by Prof. 
S. Downes (University of Nottingham, 
Nottingham, UK). HEK 293T/17 cells, NIH 3T3 
cells, HOB and opossum kidney (OK) cells were 
cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% (v/v) heat-inactivated 
foetal bovine serum (FBS), 2mM L-glutamine, 
nonessential amino acids, 100U/ml of penicillin 
and 100µg/ml of streptomycin.  CHO-K1 and HS-
mutant CHO cells were cultured in mixture F-12 
(Ham) medium (Sigma-Aldrich, UK) 
supplemented with 10% (v/v) FBS. Tetracycline 
(tet)-inducible Swiss 3T3 cells transfected with 
wild type  human TG2 were cultured and TG2 
expression induced as previously documented 
(13). Cells were all maintained at 37°C in a 5% 
CO2 humidified atmosphere. 
Vector, antibodies, kits and reagents 
The pcDNA3.1 vector and the DH5α strain of 
Escherichia coli were purchased from Invitrogen 
(Paisley, UK). All restriction enzymes were 
obtained from New England Biolabs (Knowl 
Piece, UK). Wizard plus SV Minipreps DNA 
Purification system and Wizard SV gel and PCR 
Clean-up system were obtained from Promega 
(Southampton, UK). The endotoxin-free plasmid 
DNA maxi purification kit and the human and 
mouse syndecan-4 targeting siRNAs and their 
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universal negative control siRNA were obtained 
from Qiagen (Crawley, UK). KOD HOT Start 
DNA Polymerase was obtained from Merck 
Chemical Ltd. (Nottingham, UK), QuikChange II 
site directed mutagenesis kit was from Stratagene 
(Cheshire, UK). Cell transfection kits and reagents 
including Nucleofector kit R used for transfection 
of NIH 3T3 and OK cells was from Lonza Ltd. 
(Wokingham, Berkshire, UK). Guinea pig liver 
transglutaminase (gplTG2) was purified as 
described previously (14). The synthetic peptides 
GRGDTP, GRADSP and the PKCα specific 
inhibitor Go6976 were obtained from Calbiochem 
(UK). The P1 peptide 
(NPKFLKNAGRDCSRRSS) and scrambled 
control peptide P1s (FNRADLKPRCGSSNKSR), 
the peptide corresponding to the N-terminal end of 
TG2, AEELVLERCDLELE (P2) and the 
scrambled peptide EECRLAEELLEDVL (P2s), 
the GK21 peptide 
(GENPIYKSAVTTVVNPKYEGKRQIKIWFQN 
RRMKWKK) and its scrambled control peptide 
(GTAKINEPYSVTVPYGEKNKVRQIKIWFQN
RRMKWKK) fused to the antennapedia third 
helix sequence (15) were synthesized by Peptide 
Protein Research, UK. Fibronectin and its purified 
45 and 70kDa fragments, heparin, heparinase and 
chondroitinase were purchased from Sigma -
Aldrich (UK). MMPs inhibitors were from Merck 
(UK). Antibodies used in this work are listed in 
Table 1.  
Generation of the wild type TG2 and TG2 
mutants 
Wild type (wt) human (16) and C277S mutant (17) 
TG2 were amplified by PCR using primers TG2-
F/TG2-R and cloned into the KpnI/NcoI sites of 
pcDNA3.1. The wt TG2 plasmid was then used to 
generate a set of TG2 mutants. These were 
constructed by either PCR in the case of ∆1-15 
TG2, or by using the QuickChange II site-directed 
mutagenesis kit (Stratagene, UK) for point 
mutations. Primers are shown in Table 2. The 
identity and proper arrangement of the TG2 
mutants was verified by restriction analysis and 
nucleotide sequencing.                  
Transient transfection and expression of wild 
type TG2 and TG2 mutants in human 
HEK293T/17cells, mouse NIH 3T3 cells and OK 
cells  
HEK293T/17, NIH 3T3 and OK cells, which 
express very low levels of endogenous TG2, were 
transiently transfected with wild type TG2 and the 
TG2 mutants. HEK293T/17 cells were transfected 
by the calcium phosphate procedure, while NIH 
3T3 and OK cells were transfected by 
electroporation (Lonza Nucleofector, kit R). 
Transfected cells were grown for 48 h at 37 °C in 
a 5% CO2 humidified atmosphere to allow 
expression prior to analysis. 
Syndecan-4 silencing by siRNA transfection 
The HP GenomeWide siRNA sequence targeting 
human syndecan-4 (SI00046816) (5) and siRNAs 
targeting mouse syndecan-4 (SI02691710, 
SI02714285, SI00201341 and SI02671543) and 
the non-silencing (NS) control siRNA were 
obtained from Qiagen (UK). The target sequences 
are non-homologues for any other syndecan types 
or cell surface receptors. The transfection was 
performed according to the manufacturer's 
protocol. Briefly, 3×10
5
 cells/well HOB or tet-
inducible Swiss 3T3 cells were seeded into 6-well 
plates for 24 h to reach 50-80% confluency. 150ng 
of siRNAs were used for each transfection by 
using HiPerFect transfection reagents. Following 
30-48 h siRNA transfection, cells were used in cell 
adhesion assays (5). 
Western blotting 
Cells were lysed with cell lysate buffer (Santa 
Cruz, UK).Lysates containing 50μg of protein 
were dissolved in 2× Laemmli buffer (Sigma-
Aldrich Ltd, Dorset, UK) and separated by SDS-
PAGE. Western blotting was performed using 
specific primary antibodies as described above. 
Primary antibodies were detected using the 
appropriate secondary antibody conjugated to 
horse radish peroxidase. Detection was performed 
by using ECL chemiluminescence (Amersham 
ECL™ Western Blotting System, GE Healthcare, 
UK), where applicable α-tubulin (α-Tbl) was used 
for normalization of protein loadings using 
densitometry. 
Biotinylation of cell surface proteins 
Cell surface proteins were labelled by 
biotinylation as described previously (18). Briefly, 
cell monolayers were rinsed three times with ice-
cold PBS pH 8.0 and labelled with 0.8mM sulfo-
NHS-LC-biotin dissolved in PBS pH 8.0 at 4˚C 
for 20 min. Cells were then washed with 50mM 
Tris-HCl, pH 8.0 and lysed with 1% SDS at 4˚C in 
PBS, pH8.0. Following denaturation at 95˚C, cell 
lysates were clarified by centrifugation at 
14,000×g at 20°C and 200μg of protein was 
4 
 
incubated overnight at 4°C with NeutrAvidin-
Agarose resin. After washing three times with PBS 
pH 8.0, the biotin-labelled proteins were dissolved 
in 2× Laemmli buffer separated by SDS-PAGE 
and subjected to Western blotting. Cell surface 
levels of TG2 shown were normalised, using 
densitometry, to the total cell lysate values after 
the latter had been corrected for protein loading 
using α-tubulin. The wt cells were used as the 
100% control. Value shown represents the mean 
values from 2 separate experiments unless stated 
otherwise. 
Detection of TG2 in the ECM 
Following transfection, cells were incubated for 24 
h with 10% (v/v) serum, which was replaced with 
1% (v/v) serum and TG2 expression and matrix 
deposition was allowed to proceed for a further 24 
h, were then detached with 2mM EDTA in PBS, 
pH 7.4 and the ECM was extracted with 0.1% 
(w/v) deoxycholate in PBS, pH 7.4. The residual 
deoxycholate-insoluble ECM proteins were 
dissolved in 2× Laemmli buffer for further 
analysis by SDS-PAGE and Western blotting 
using Cub7402.  
To detect the presence of TG2 in the ECM of TG2 
transfected tet-inducible Swiss 3T3 cells, the cells 
were seeded into 6-well plates at the density of 
3×10
5
 cell/well. TG2 expression was induced by 
withdrawing tetracycline from the culture system 
(tet- cells), while cells cultured in the presence of 
tetracycline (tet+ cells) were used as the control. 
After induction of TG2 expression in the presence 
of certain treatments for 48 h, the cells were lifted 
with 2mM EDTA in PBS, pH 7.4 and lysed in cell 
lysis buffer and used as the cell lysate fractions, 
The ECM fractions were washed once and 
collected into 2× Laemmli buffer. Western 
blotting was performed to detect the target 
proteins by using specific antibodies. The 
treatments included: general MMP inhibitor 
GM6001, MMP-2/9 inhibitor, MMP-3 inhibitor 
and MMP-8 inhibitor at the concentration of 
10μM, 10μg/ml heparin, 15mU/ml heparinase or 
chondroitinase, 0.5μM PMA or 5µM PKCα 
inhibitor Go6976. Matrix levels of TG2 shown 
were normalized to the total cell lysate values 
using densitometry after the latter was corrected 
for protein loading using α- tubulin. The wt cells 
or for the Swiss 3T3 cells the untreated cells, were 
used as the 100% control with values shown 
represented as a percentage of this. Values shown 
represent the mean values from 2 separate 
experiments unless stated otherwise. 
Dot blotting for ECM syndecan-4 
To detect the presence of the shed syndecan-4 
ectodomain in the ECM, modified dot blotting was 
applied. Briefly, tet-inducible 3T3 cells were 
seeded into 12-well plates at the density of 2×10
5
 
cells/ well and induced for TG2 expression for 48 
h with the treatments (including PMA, Go6976, 
and the MMP-2/9 inhibitor) as described for TG2. 
The matrix fractions were then collected as 
described for the matrix TG2 and then dissolved 
into 2× Laemmli buffer. The ECM fractions 
containing equal amounts of protein were then 
loaded onto nitrocellulose membranes under 
vacuum using a dot blotter, washed and blocked 
with blocking buffer (5% (w/v) dried fat-free milk 
dissolved in TBS-Tween, pH 7.4) and the presence 
of syndecan-4 detected by immunoprobing with a 
specific antibody recognizing the ectodomain of 
syndecan-4.  
Measurement of TG2 binding to FN by ELISA 
Microtitre 96 well plates were coated with 50µl of 
5µg/ml FN in 50mM Tris-HCl, pH 7.4 at 4°C 
overnight. The wells were blocked for 30 min with 
3% BSA in PBS, pH 7.4 and washed twice with 
PBS-Tween, pH 7.4 and once with PBS, pH 7.4. 
Aliquots (100µl) of cell lysate containing 60μg 
protein were added to the FN-coated wells and 
incubated for 1 h at 37˚C. After washing three 
times with PBS, pH 7.4, wells were blocked with 
100µl 3% BSA in PBS, pH 7.4 for 30 min at room 
temperature and then incubated with 100µl 
Cub7402 (1:1000 dilution in blocking buffer) for 2 
h at 37˚C. After washing three times with PBS, pH 
7.4, the wells were incubated with 100µl rabbit 
anti-mouse IgG-HRP conjugated antibody (1:1000 
dilution in blocking buffer) for 2 h at 37˚C. HRP 
was detected by the addition of 100µl of o-
phenylenediamine substrate solution (Sigma Fast 
OPD, Sigma). Colour development was terminated 
by the addition of 50µl of 2.5M H2SO4 and 
absorbance at 490nm was measured. The amount 
of TG2/mutant TG2 binding to the FN was 
normalised between samples by using the 
densitometry values from Western blotting for the 
TG protein found in each of the cell lysates used. 
Α-Tubulin was used to normalise for any 
differences in protein loading. 
Inhibition of purified TG2 binding to FN by 
TG2-derived peptides 
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96-well  Microtitre 96-well plates were coated 
overnight with either full length FN (5μg/ml) or its 
N-terminal fragments of 45kDa (54μg/ml) or 
70kDa (45μg/ml) fragments which contain the 
TG2 binding site , in 50mM Tris-HCl, pH 7.4 as 
previously described (6,19). Wells were blocked 
with 3% BSA (w/v) in TBS pH 7.6. After three 
washes with PBS pH7.4, competitive peptides 
diluted in PBS, 2mM EDTA, pH 7.4 were added 
to the wells at concentrations from 10μM – 1mM 
and incubated for 1 h at room temperature. Wells 
were washed three times with PBS pH7.4 and 
purified human recombinant TG2 was added at a 
final concentration of 2μg/ml in the presence of 
the different concentrations of P2 or P2s peptides 
and incubated for 1 h at room temperature. After 
three washes with PBS pH7.4 bound TG2 was 
measured via ELISA as introduced above.  
For the binding ability of TG2 when in either the 
fully closed or open conformation, gplTG 
(20mg/ml) was reduced by pre-incubation with 
1mM DTT and then diluted (at least 20 fold) in 
PBS, pH 7.4. The reduced gplTG 20μg/ml was 
pre-incubated with 1mM GTP or GTPγS (closed 
conformation) or TG2 site directed irreversible 
inhibitors R281 or R283 (extended conformation) 
at the concentration of 500μM (in the presence of 
10mM Ca
2+
) at room temperature for 30 min. 
Treated enzymes were then incubated with the 
FN-coated wells at 37°C for 1 h as described in the 
Materials and Methods. 20μg/ml gplTG in 2mM 
EDTA in PBS, pH 7.4 was used as the positive 
control and 2mM EDTA in PBS, pH 7.4 was used 
as the negative control. TG2 bound to FN was 
detected via ELISA as described in the Materials 
and Methods. Values represent the mean ± S.D. 
absorbance at 450nm from 3 experiments.  
Binding of TG2 to heparin Sepharose 
HEK cells, transiently transfected with wild-type 
and mutant TG2 were washed twice with ice cold 
PBS, pH 7.4, and lysed by the addition of 150 µl 
of 20mM Tris-HCl pH 7.4, 10mM EGTA, 2mM 
EDTA, 1mM NaF and 1mM Na3VO4. After 
clarification by centrifugation (300×g for 10 min), 
cell lysates were mixed with 450µl of 50mM Tris-
HCl, 1mM EDTA, 1mM DTT, pH 7.5 and applied 
to a 5ml Heparin Sepharose column (GE 
Healthcare) equilibrated in 50mM Tris-HCl, 1mM 
EDTA, 1mM DTT pH 7.5 (buffer) at a flow rate of 
1ml/min. For the analysis of GTP-bound TG2 
(closed conformation), lysates were pre-incubated 
for 1 h at room temperature with 0.5mM GTP in 
50mM Tris-HCl, 2mM MgCl2, 1mM EDTA, 1mM 
DTT pH 7.5. For the analysis of inhibitor-reacted 
TG2 (open conformation), lysates were incubated 
with 0.5mM of irreversible inhibitor R281 (20) 
and 10mM CaCl2. The column was washed with 
25ml of buffer and protein was eluted with a linear 
gradient of increasing NaCl concentration (0-1M) 
in buffer. Fractions were assayed for TG2 activity 
and analysed for the presence of TG2 antigen by 
SDS-PAGE and Western blotting using CUB7402. 
Measurement of TG activity in cell lysates and 
heparin Sepharose fractions 
TG activity in column fractions was measured by 
biotin X-cadaverine incorporation into N,N’-
dimethylcasein as described previously (21). After 
coating the wells with 100µl of 10mg/ml N,N’-
dimethylcasein in 50mM Tris-HCl, pH 8.0, plates 
were  washed with TBS-Tween, pH 7.6 and TBS, 
pH 7.6, and 50µl of column flow-through as well 
as each eluted fraction was added into the coated 
wells. Additionally 50µl of 100mM Tris-HCl pH 
8.0, 0.25mM biotin X-cadaverine, 10mMDTT, 
20mM CaCl2 (or 5mM EDTA as control) was 
added into each well. The reaction was allowed to 
proceed for 1 h at 37°C. The plate was then 
washed once with TBS-Tween, pH 7.6 and TBS, 
pH 7.6 before being blocked with 100μl of 3% 
(w/v) BSA in TBS, pH 7.6, for 30 min at 37°C. 
After another wash, biotin X-cadaverine 
incorporation into N,N’-dimethylcasein was 
detected by incubation for 1 h at 37°C with 100μl 
Extravidin-peroxidase (Sigma-Aldrich, UK) 
diluted 1:2000 in 3% (w/v) BSA in TBS, pH 7.6. 
After another set of washes, TG2 activity was 
measured using Sigma Fast OPD, tablets dissolved 
in 20ml of distilled H20. The colour was developed 
by adding 2.5M H2SO4 and the absorbance at 
490nm measured using a microplate reader.  
For cell lysates the incorporation of biotin-X-
cadaverine into FN as described previously was 
used (21). Briefly, wells of 96-well plate were 
coated with 5 µg/ml of FN in a 50mM Tris-HCl, 
pH 7.4 and incubated overnight at 4°C. After 
washing with 50mM Tris-HCl, pH 7.4, wells were 
blocked with 3% (w/v) BSA in 50mM Tris-HCl 
pH 7.4 for 30 min at 37°C. Enzyme reactions 
contained  50µg of cell lysate protein  in  50mM 
Tris-HCl pH 7.4 buffer containing 5mM CaCl2 (or 
5mM EDTA as control), 10mM DTT, 0.132mM 
biotin X-cadaverine each done in triplicate. 
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Reactions were allowed to proceed for 2 h at 37°C. 
Plates were then processed as described above. 
Cell adhesion assays 
The cell adhesion assay was carried out as 
previously described (18). Briefly, 96-well plastic 
tissue culture plates were coated with 5µg/ml FN 
in 50mM Tris-HCl, pH 7.4 at 4°C overnight, after 
washing three times with 100µl of 50mM Tris-
HCl, pH7.4, gplTG (20µg/ml) in 2mM EDTA in 
PBS, pH 7.4 was added to the wells for 1 h at 37˚C 
and the wells were washed three times with 50mM 
Tris-HCl, pH7.4. Serum-starved (for 16 h) HOB 
cells with different treatments as introduced below 
in serum-free medium were detached by 
trypsinization and then treated with trypsin 
inhibitor. Cells were washed three times with 
serum free medium and seeded onto either FN or 
TG-FN matrix for 20-40 min. Peptides P1 or 
scrambled P1 (P1s), were added at concentrations 
between 100µg/ml and 300µg/ml. To determine 
the RGD-independent cell adhesion, assays were 
performed by incubating cells with either RGD or 
RAD peptide (100µg/ml) unless stated otherwise 
in the presence of the P1 or P1s peptides for 20 
min prior to seeding of the cells. Attached cells 
were washed once with PBS, pH 7.4 and then 
fixed with 3.7% paraformaldehyde, further 
permeabilized with 0.1% (v/v) Triton-X in PBS, 
and co-stained with May-Grunwald and Giemsa 
stains as described previously (5). Images of 
stained cells from non-overlapping fields of view 
were photographed at 20× magnification and 
analyzed using the imaging analysis program 
Scion Image (National Institute of Health). Cell 
attachment and spreading were quantified, and the 
number of cells per image was assessed as 
described previously (19). Cell attachment on FN 
without peptide was considered as the control 
value for all the experiments unless stated 
otherwise. The mean number of attached cells 
from at least three wells was calculated and that of 
the control was considered as 100%. The mean 
number of attached cells (cell attachment) for each 
sample was then expressed as the percentage of 
cell attachment on FN. The mean percentage of 
attached cells that are spread (cell spreading) for 
each sample was determined separately, and the 
mean percentage of spread cells on FN control was 
expressed as 100%. The mean percentage of 
spread cells for each sample was then normalised 
against that of FN control. Cell attachment on FN 
without the RGD peptide was considered as the 
control value for most of the experiments unless 
stated otherwise.  The mean number of attached 
cells from three wells was calculated and that of 
the control was considered as 100%. The mean 
number of attached cells (cell attachment) for each 
sample was then expressed as the percentage of 
cell attachment on FN. The mean percentage of 
attached cells that are spread (cell spreading) for 
each sample was determined separately, and the 
mean percentage of spread cells on the FN control 
was expressed as 100%. The mean percentage of 
spread cells for each sample was then normalised 
against that of FN control. Cell pre-treatments 
included: PKCα inhibitor Go6976 (5µM) or GK21 
peptide (8µM, which blocks the interaction 
between PKCα and the intracellular domain of β1 
integrins) for 1 h in serum-free medium prior to 
cell detachment; heparinase (15mU/ml) or 
chondroitinase (15mU/ml) to cells in suspension in 
serum free medium for 1 h; or α5β1 integrin 
blocking antibody NKI-SAM-1 and its isotype 
control antibody (20µg/ml) in serum free medium 
for 1 h. For the detection of the signalling 
molecules via Western blotting, the cell adhesion 
assay was performed in 60mm Petri dishes and 
cells were collected into cell lysis buffer (Santa 
Cruz, UK) as described previously and pre-cleared 
by centrifugation at 300×g for 10 min. Western 
blotting was performed with specific anti-p-397 
FAK or p-ERK1/2 antibodies. Membranes were 
stripped (19) and total FAK and ERK1/2 detected 
using anti- FAK and anti- ERK1/2 antibodies as 
listed in Table 2, while α-tubulin was used as an 
equal loading standard (5). 
Fluorescence Staining 
Cell adhesion on FN matrix in the presence of 
either the P1 or the P1s peptide (100μg/ml) was 
performed as described above. Cells were seeded 
in 8-well glass chamber slides (8×10
4
cells/well) 
previously coated with FN and allowed to attach 
and spread for 20-40 min. Cells were fixed and 
permeabilized as described above and then 
blocked with 3% BSA in PBS, pH 7.4, (the 
blocking buffer) for 30 min. For the actin stress 
fibre staining, the cells were incubated with FITC-
labelled Phalloidin (20μg/ml) in blocking buffer. 
For the focal contact staining in HOB cells, after 
treatment with blocking buffer, the cells were 
incubated with anti-Vinculin antibody (1:100 
dilution) followed by anti-mouse IgG-TRITC at 
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37˚C for 2 h/incubation. Slides were mounted with 
Vectashield mountant (Vector Laboratories) and 
examined via confocal microscopy (5). 
For the FITC-cadaverine incorporation in situ 
assay, tet-inducible Swiss 3T3 cells were seeded 
into 8-well chambers at the density of 
7×10
4
cells/well. Together with the withdrawal of 
the tetracycline, the cells were treated with PKCα 
inhibitor Go6976, MMP-2/9 inhibitor, MMP-8 
inhibitor, heparin and heparinase as described 
above. After 48 h induction of TG2 expression, 
fresh medium with 0.5mM FITC-cadaverine (with 
or without the treatment) was incubated with the 
cells at 37˚C for 1 h. The wound was introduced 
into the mono-cell layer using a sterile plastic 
pipette tip and the cells were incubated for another 
1 h as described previously (22). After washing 
three times with PBS, pH 7.4, the cells were fixed 
with methanol at -20˚C for 10 min and then 
mounted in Vectorshield mountant medium and 
the fluorescence signal detected by fluorescence 
microscopy.  
Co-immunoprecipitation assay for the interaction 
between TG2 and syndecan-4 
Tet-inducible Swiss 3T3 cells (5×10
5
cells/well) 
were seeded into 6-well plate and TG2 expression 
was induced by withdrawing tetracycline from the 
cell culture system. 200μg/ml of P1 or P1s peptide 
was used together with the TG2 induction. The 
cell lysates were collected into the co-IP buffer 
and co-IP was performed to detect the interaction 
between TG2 and syndecan-4 as introduced 
previously [14]. Briefly, 0.5μg of anti-syndecan-4 
antibody was used to pull down the syndecan-4-
immunocomplex from the precleared cell lysates 
and Western blotting was carried on to detect the 
presence of TG2 in the immunocomplex by using 
specific anti-TG2 antibody Cub7402. The non-
induced Swiss 3T3 cells with the undetectable 
TG2 expression were used as the negative control.   
Solid binding assay for the P1 peptide binding to 
syndecans 
To detect the binding specificity of P1 peptide 
toward syndecan-4 and syndecan-2, ELISA plates 
were coated with P1 peptide at the concentration 
of 1µg/ml in Na2CO3 solution pH 9.6 at 4˚C for 
overnight. The wells were blocked with 3% BSA 
in PBS, pH 7.4 after washing with 50mM Tris-
HCl, pH 7.4. 2µg/ml recombinant human 
syndecan-4 or syndecan-2 (with the his-tag) in 
50mM Tris-HCl, pH 7.4 was incubated with the 
wells at 37˚C for 1 h. The presence of syndecan-4 
or syndecan-2 bound to the peptide-coated wells 
was detected by using anti-His tag antibody and 
anti-mouse secondary. The signals were detected 
by using OPD substrate and the absorbance was 
measured at 490nm.    
Docking studies 
The crystal structures 1KV3 and 2Q3Z were 
downloaded as pdb files from the Protein Data 
Bank (http://www.rcsb.org/) and opened in the 
software CAChe WorkSystem Pro version 
7.5.0.85 (Fujitsu Ltd). Hydrogens were added and 
waters and ions were deleted. The hydrogen atom 
positions were relaxed by conducting a MM2 
geometry optimisation for each structure where all 
the non-hydrogen atom positions were locked. For 
the HS1 site, docking sites were defined by 
selecting all the amino acid residues within either 
5 Å or 8 Å of residues K600, R601 and K602. For 
the HS2 site, docking sites were defined by 
selecting all the amino acid residues within either 
5 Å or 8 Å of residues K202, K205, R209, R213 
and R222. Both crystal structures contained 
missing residues but these were far enough away 
from the defined docking sites such that their 
absence would not interfere with the docking 
studies. Using the same software, three ligand 
structures (a dimer, a pentamer and a hexamer) 
were defined by taking residues 2-3, 2-6 and 2-7 
respectively from the glycosaminoglycan structure 
1HPN.pdb. Using the Project Leader module and 
the Active Site docking component of the same 
software, the three ligands were each docked three 
times into the defined docking sites of both 
proteins using the flexible ligand and flexible 
active site side chain options. Other parameters 
and options included: Use Amber van der Waals; 
population size 50; maximum generations 3000; 
crossover Rate 0.8; mutation Rate 0.2; elitism 
number 5; local search rate 0.06; maximum 
iterations local search 300. 
Data analysis  
Results shown are the mean ± S.D. unless 
otherwise stated. The differences between data 
calculated was undertaken by Student’s t-test and 
indicated as significant when the p < 0.05. 
 
RESULTS 
Identification of putative heparin-binding motifs 
in TG2 
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HS-binding motifs may be  composed of basic 
amino acid-containing sequences, such as 
XBBXBX or XBBBXXBX, where B is a basic 
amino acid whose side chain is exposed on the 
protein surface and X is a neutral or hydrophobic 
amino acid, whose side chain is directed towards 
the protein interior (23). Examination of the 
primary amino acid sequence of TG2 for these 
linear consensus HS binding motifs revealed one 
such sequence 
261
LRRWKN
266
 close to the active 
site of TG2 (Figure 1A) (24). Examination of the 
crystal structure of TG2 (1KV3) shows that 
261
LRRWKN
266
 is part of an alpha helix, whereas 
the XBBXBX consensus must be in a β-sheet in 
order for the basic residues to face the same 
direction. A common structural theme of linear HS 
binding motifs is that there are two basic residues 
approximately 20Å apart to accommodate a 
pentasaccharide, facing in opposite directions on 
an alpha helix (25). Since 
261
LRRWKN
266
 is too 
short to satisfy this requirement it is unlikely to be 
able to bind HS and so was ruled out. The three 
dimensional arrangement of basic amino acid 
residues is likely to be more important than linear 
clustering, such that many HS binding motifs can 
also be comprised of sequence-distant basic amino 
acid residues (26). Examination of the crystal 
structure of TG2 revealed two likely candidate 
motifs, 
590
KIRILGEPKQKRK
602
 (HS1) which is 
located at the tip of C-terminal β barrel 2 and 
another comprised of 
202
KFLKNAGRDCSRRSSPVYVGR
222
 with K387 
(HS2), forming a shallow pocket lined with basic 
residues (Figure 1A-C). Importantly both of these 
sites are likely to allow simultaneous binding of 
fibronectin (Figure 1A) as previously described 
(6,19,27). 
A heparin-derived oligosaccharide docks into a 
characteristic heparin binding pocket in TG2 
The HS1 and HS2 regions were docked with 
heparin derived oligosaccharides. An iduronic 
acid-2-sulphate-glucosamine-2, 6-disulphate 
disaccharide, which is the most common repeating 
unit of heparin This docked better with the HS2 
region than the HS1 region of the closed form of 
TG2 (1KV3) although both sites docked well .A 
pentasaccharide and a hexasaccharide with the 
same repeating units bound with a similar enthalpy 
to both the HS2 and HS1 site (see Figure 1D and 
E). The same oligosaccharides failed to dock as 
successfully with the open conformation of TG2 
(2Q3Z) at both the HS1 and HS2 sites although 
slight preference was shown for the HS1 site 
(Supplementary Table 1). 
Expression of the FN and HSPG TG2 mutants in 
mammalian cell systems   
Mutant TG2 enzymes for the binding of FN 
(D94A, D97A), the N-terminal deletion (Δ1-15) 
and HS mutants HS1 (K600A, R601A, K602A) 
and HS2 (K205A, R209A) were generated by 
mutagenesis of plasmid pcDNA3.1-TG2. Mutants 
were confirmed by nucleotide sequencing and 
transfected into HEK293T/17 and NIH 3T3 cells 
to assess expression. All mutants were expressed 
in both cell types (Figure 2A and 2D) and by 
Western blotting showed bands of the expected 
molecular weight (Figure 2A and 2D) although at 
slightly different levels, with the Δ1-15 TG2 
mutant showing significantly less expression in 
both cell types  when compared to the wt cells 
(Figures 2B, C, E and F). Comparable 
transamidating activities were found with all 
mutants when normalised to TG2 protein (Figure 
2C and 2F) apart from the Δ1-15 TG2 mutant 
which was significantly lower (approx 50%) than 
the wt enzyme in HEK293T/17 cells but still 
present, suggesting no evidence for gross 
misfolding. 
The high affinity heparin binding site of TG2 is 
located in the catalytic core domain 
TG2 binds to heparin Sepharose with high affinity, 
and has been used for its purification. The binding 
strength of TG2 and mutants HS1 and HS2, 
expressed in HEK 293T/17 cells, to heparin 
Sepharose was determined by elution with an 
increasing salt gradient (Figure 3A). TG2 was 
eluted over a very broad peak ranging from 
100mM NaCl to 500mM NaCl with optimum 
elution at 330mM NaCl. To rule out that the 
observed low affinity binding was due to 
denatured TG2, the transglutaminase activity of 
eluted fractions was determined and this showed 
that specific activity did not differ significantly 
between fractions (Supplementary Figure 1). 
Mutant HS1 bound heparin identically to TG2, 
with low and high affinity, whereas HS2 lost its 
high affinity binding to heparin, with a large 
percentage of the mutant showing no binding to 
the heparin column and the remainder showing 
low affinity binding, eluting at a NaCl 
concentration of 60mM (Figure 3A), suggesting 
that residues K205 and R209 contribute to the high 
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affinity binding to heparin. Since mutant HS1 had 
a higher net charge reduction than HS2, this 
alteration in HS2 binding was not simply due to 
electrostatic interaction. Comparable studies with 
the D94A, D97A FN mutant showed this mutant 
had a comparable elution profile to the wt enzyme. 
However, the Δ1-15 TG2 FN binding mutant 
showed only a low affinity binding to the heparin 
column with the major peak eluting at around 
250mM NaCl. 
High affinity heparin binding is dependent on 
TG2 conformation 
Since TG2 can adopt two extremes of 
conformation in the presence or absence of GTP, 
the effect of GTP binding on the association of 
TG2 to heparin was also investigated (Figure 3A). 
In the presence of GTP, which results in a compact 
globular conformation, all of the TG2 bound with 
high affinity to heparin with the major peak 
eluting at about 330mM NaCl,  In contrast, after 
reaction with the irreversible peptidic inhibitor 
R281 (20) or mutation of the active site Cys
277
 to 
Ser, which restricts the conformation to an 
extended form, the TG2 bound to heparin with 
lower affinity with the major peak eluting at 
250mM NaCl. Since the GTP-bound globular 
form of TG2 bound to heparin with high affinity 
whilst the extended R281-bound form still retained 
an affinity greater than that of the HS2 mutant, this 
suggests that the loss of high affinity binding of 
HS2 is not solely due to an altered conformation. 
Hence, TG2 residues K205 and R209 are very 
likely to be directly involved in high affinity 
heparin binding. 
Studies with the HS2 peptide 
NPKFLKNAGRDCSRRSS (P1) 
Our previous studies (6,19,27) indicated that TG2, 
when regulating cell adhesion via syndecans, 
interacted directly with syndecan-4, but not 
syndecan-2 which was activated indirectly via 
PKCα.  We therefore tested the binding specificity 
of the TG2 HS2 region toward these two 
syndecans. A peptide 
200
NPKFLKNAGRDCSRRSS
216
 (P1), which 
mimics the heparin binding domain in TG2, was 
synthesized. This peptide was chosen for its 
potential to fold correctly and the hydrophobic C-
terminal sequence PVYVGR, which may affect 
solubility, was excluded. A solid binding assay 
was undertaken to study the binding ability of this 
peptide toward syndecan-4 and syndecan-2, in 
which his-tagged recombinant human syndecan-4 
or syndecan-2 was assessed for their binding to the 
immobilised P1 peptide and then detected by using 
anti-his tag antibody. As shown in Figure 3B, 
strong preference was shown for syndecan-4 
binding to the P1 peptide when compared to the 
binding of syndecan-2, suggesting that the binding 
specificity of the P1 peptide towards syndecan-4 
confirms our previous findings that TG2 binds 
preferentially to the heparan sulphate chains on the 
cell surface syndecan-4 and not syndecan-2 (6). 
Using immunoprecipitation, we further tested the 
competitive effect of the P1 peptide for the 
interaction between syndecan-4 and TG2. To 
confirm this specificity and to rule out any 
potential toxicity of the P1 peptide to the cells, a 
scrambled peptide (P1s, 
FNRADLKPRCGSSNKSR) was also used. 
Figure 3C shows that the immunoprecipitation of 
TG2 with anti- syndecan-4 antibody was reduced 
around 50% in the presence of the P1 peptide, but 
no effect was found with the scrambled analogue, 
thus confirming the specificity of the P1 peptide 
for syndecan-4.  
Using cell studies, we then investigated if the 
peptide P1 can mimic TG2 in cell adhesion studies 
and as such can either substitute for or abolish the 
TG2-mediated compensation of the RGD-
mediated loss of cell adhesion. In our earlier 
studies using both HOB and mouse embryonic 
fibroblast (MEF) cells, it was shown that 
extracellular TG2 bound to matrix FN could 
compensate for the loss of integrin-mediated cell 
adhesion in the presence of RGD peptides in a 
process requiring cell surface syndecan-4, but not 
its transamidase activity (27). Since direct 
interaction of TG2 with syndecan-4 is essential for 
this process, the HSPG binding properties of TG2 
are therefore critical. The P1 peptide was tested for 
its ability to compensate the RGD-induced loss of 
cell adhesion on FN in HOB cells. At a peptide 
concentration between 0.01-200μg/ml, significant 
compensation started as low as 5-10μg/ml with 
maximum compensation achieved between 50-
100µg/ml (Figure 4A). We then investigated 
whether the P1 peptide, when used at a 
concentration of 100µg/ml, could compete for the 
binding of syndecan-4 and abrogate the 
compensatory effects of TG-FN, when the cells 
were plated onto the TG-FN matrix in the presence 
of the RGD peptide. Figure 4B shows that P1 
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peptide only has a small, but not significant dose-
dependent negative effect on the attachment and 
spreading of HOB cells on TG-FN in the presence 
of the RGD peptide, whereas the scrambled 
control peptide P1s had almost no effect. This 
suggests that even though the peptide may 
compete for TG2 for the syndecan-4 binding site 
its ability to mimic TG2 in compensating RGD-
induced loss of cell adhesion means no large 
changes in cell adhesion are likely to be observed. 
Neither peptide significantly affected the binding 
of cells to FN alone when used at similar 
concentrations of 100-300μg/ml, although a small 
(approx 10%) but significant enhancement of 
adhesion was found for P1 peptide when 
compared to the P1s peptide (Figure   4B). 
Importantly, the TG2 mimicking P1 peptide was 
able to restore actin cytoskeleton formation and 
focal adhesion assembly, which was disrupted 
with the RGD peptide (Figure 5A and B), while 
the scrambled analogue 
FNRADLKPRCGSSNKSR (P1s) showed no 
effect on either of these.  
P1 peptide acts via binding and activation of 
syndecan -4-mediated cell signalling  
Further confirmation that the P1 peptide can act 
like extracellular TG2 in compensating α5β1 
integrin loss (6) of cell adhesion was shown by 
pre-incubated cells with the P1 peptide prior to 
incubation with the α5β1 integrin blocking 
antibody (NKI-SAM-1). The P1 peptide led to a 
significant increase in cell adhesion in the 
presence of the inactivating antibody when 
compared to the control cells incubated with the 
antibody in the presence and absence of the P1 
scrambled peptide (Figure 6A). 
To test the importance of cell surface HS in the 
binding of P1 peptide, HOB cells were pre-treated 
with heparinase or chondroitinase prior to the cell 
adhesion assay. Treatment with heparinase, but not 
chondroitinase, abolished the compensatory effect 
of the P1 peptide on the RGD-induced loss of cell 
adhesion (Figure 6B). To confirm that the P1 
peptide is binding to cell surface syndecan-4 
molecules, HOB cells were treated with syndecan-
4 siRNA and scrambled control siRNA as 
previously documented (5). As previously found 
(5) treatment of HOB cells with syndecan-4 
siRNA led to a around 50% reduction in protein 
expression (Supplementary Figure 2A) without 
affecting either syndecan-2 or β1 integrin 
expression, another two major players in the TG-
FN complex-mediated signalling pathway (18). 
This loss in expression of syndecan-4 led to a 
comparable but significant reduction in the 
compensatory effect for the P1 peptide on the 
RGD-induced loss of cell adhesion (Figure 7A). 
The scrambled siRNA had no significant effect on 
either expression or cell adhesion, further 
confirming the essential role of syndecan-4 in the 
P1 peptide-related cell adhesion process.   
Our next step was to demonstrate the activation of 
protein kinase C α (PKCα) in the signalling effects 
mediated by the P1 peptide. The PKCα inhibitor 
Go6976 and the GK21 peptide (which is reported 
to compete with the PKCα binding site on β1 
integrin (15) both inhibit PKCα activation events 
leading to a significant loss of the compensatory 
effect of the P1 peptide on the RGD-induced loss 
of cell adhesion (Figure 7B and C), strongly 
suggesting that the P1 peptide is acting in a 
comparable signalling manner to that of TG2. To 
confirm our observations that the P1 peptide is 
inducing intracellular signalling pathways 
comparable to the TG-FN matrix, we looked at the 
activation of focal adhesion kinase (FAK) by 
phosphorylation at Tyrosine 397 (Figure 8A and 
8B) and phosphorylation of extracellular-signal 
regulated kinase1/2 (ERK1/2) (Figure 8C and 
8D). In each case, in the presence of RGD and P1 
peptide the compensation of the RGD-induced loss 
of adhesion was paralleled by a significantly 
greater phosphorylation of p-FAK
397
 than that 
found with the P1s peptide, thus confirming the 
ability of the P1 peptide to restore focal adhesion 
assembly and activation of p-ERK1/2 (Figure 8A-
D).  
The N-terminus of TG2 is involved in FN 
binding 
The Δ1-15 and D94A, D97A TG2 mutants were 
assessed for their ability to bind to FN in a solid 
phase binding assay utilising purified FN and 
clarified lysates from HEK 293T/17 cells 
transfected with the different mutants. The D94A, 
D97A mutant described previously (28) 
demonstrated significantly less binding 
(approx50%) compared to wild type TG2, whereas 
the Δ1-15 deletion mutant previously described 
(28) had approximately 60% less (p< 0.05) 
binding capacity of the wild type (Figure 8E). A 
competitive peptide corresponding to the N-
terminal deletion site of TG2 
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2
AEELVLERCDLELE
15
 (P2) (TG2 undergoes N 
terminal post-translational modification of the N-
terminal methionine) was tested for its ability to 
inhibit wild type TG2 binding to FN and the 
smaller TG2 binding N-terminal FN fragments of 
45 and 70kDa in a solid binding assay. The P2 
peptide resulted in a moderate but significant 
inhibition of binding to FN and its smaller 
fragments at higher concentrations(500µM-1mM) 
of the peptide not shown with the scrambled P2s 
peptide (Figure 8F and 8G), suggesting that the 
N-terminal residues 1-15 of TG2 may be 
important for FN binding, in addition to the 
published D94A, D97A site. However, the limited 
inhibition seen with this peptide suggests that the 
FN binding site around the N-terminal site of TG2 
may be more complex and that a larger structural 
unit than that described previously (28) may be 
involved in FN binding. 
HS binding is required for ECM localisation of 
TG2  
Since TG2 has been shown to have a high affinity 
binding for heparan sulphates (29), we 
investigated the ability of the FN and HS-binding 
mutants to be secreted to the cell surface and/or 
deposited into the ECM. Using transfected NIH 
3T3 fibroblasts, the cellular localisation of the 
D94A, D97A FN mutant, the Δ1-15 mutant and 
the HS1 and HS2 TG2 mutants were tested for 
their presence at the cell surface using the cell 
surface biotinylation assay. For detecting the 
presence of these mutant TG2s in the ECM, 
transfected NIH 3T3 cells were used, which 
actively deposit ECM. The TG2 Δ1-15 mutant was 
not detected on the cell surface of the NIH3T3 
cells (Figure 9A) whereas the HS2 mutant was 
detected but in very reduced amounts compared to 
the wild-type TG2. The levels of the FN mutant 
D94A, D97A and the HS1 mutant were found at 
comparable levels on the cell surface to that shown 
for the wild-type TG2 (Figure 9A). A comparable 
picture was observed for the presence of the TG2 
wt and mutants in the ECM of NIH 3T3 cells apart 
for the HS2 mutant and the Δ1-15 mutant which 
were barely or not detectable respectively within 
the matrix (Figure 9B).  
Cellular localisation of TG2 in CHO wt and 
CHO-HS-M cells  
To confirm the importance of cell surface HS in 
the cell surface distribution of TG2, the HS 
deficient Chinese hamster ovary-K1 (CHO-K1) 
cells derivative pgsD-677 were compared to wt 
CHO-K1 cells with respect to their distribution of 
TG2 at the cell surface (Figure 9C and 9D), which 
clearly demonstrates that the amount of TG2 
found at the cell surface in the CHO mutant cells 
is considerably reduced when compared to the wt 
cells.  
The involvement of syndecan shedding in 
deposition of matrix TG2 
We next determined whether cell surface syndecan 
shedding may be a possible mechanism for 
translocating HS-bound TG2 into the extracellular 
matrix. Since MMPs are reported to be involved in 
the shedding of cell surface HS into the ECM (12), 
a general MMP inhibitor GM6001 was first used 
to treat TG2 transfected Swiss 3T3 cells. TG2 
expression can be induced in these cells via the 
tet-inducible promoter and is  externalised and 
deposited into the matrix in large amounts (27). 
Following induction of TG2 by withdrawal of 
tetracycline (tet-) from the cell culture system, the 
matrix deposited TG2 is detectable after a 48 h 
induction (Figure 10A). In the presence of the 
MMP inhibitor GM6001 (10μM) the matrix 
deposited TG2 was very much reduced although 
expression of TG2 was not affected. The negative 
control treatment did not show any effect on TG2 
expression and deposition (Figure 10A). To 
clarify which member(s) of the MMP family 
members are involved in the TG2 deposition, 
specific MMP inhibitors against MMP-2/9, MMP-
3, MMP-8 were used. As shown in Figure 10B, 
the MMP-2/9 inhibitor reduced the matrix TG2 
deposition by around 50%, which was not 
apparent in the other MMP inhibitor treated cells. 
This suggests that the MMP-2/9 inhibitors which 
are the major MMP members participating in 
wound healing and HS shedding (12,30), are also 
involved in ECM TG2 deposition. Different 
treatments (12,31) known to affect HS shedding 
were then used in the tet-inducible 3T3 cells. 
Figure 10C shows that PMA, an enhancer for HS 
shedding (31), slightly increased the amount of 
matrix TG2, while the PKCα inhibitor Go6976 (an 
inhibitor for HS shedding (12)) blocked deposition 
of TG2 into the ECM. Heparin (at the 
concentration of 10μg/ml), a known protector of 
MMP-dependent HS shedding (32), reduced the 
presence of TG2 in the matrix, while heparinase 
(which digests the cell surface HS chains) 
completely inhibited matrix TG2 deposition. In 
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contrast chondroitinase did not show any effect on 
matrix TG2 deposition (Figure 10C). By using 
syndecan-4 siRNA targeting mouse syndecan-4, 
the expression of syndecan-4 was reduced to 
around 50% compared to the non silencing (NS) 
control (Supplementary Figure 2B), which led to 
a comparable reduction of ECM deposited TG2 
deposition (Figure 11A). To confirm that 
comparable levels of syndecan-4 to that found for 
TG2 are  found in the ECM following treatment of 
cells with the same key modulators of syndecan 
shedding. The matrix of the treated cells was 
collected and immunoprobed for the presence of 
syndecan-4. As shown for TG2, PMA, an 
enhancer of syndecan shedding, increased the 
amount of syndecan-4 present in the ECM, while 
the inhibitors of shedding PKCα inhibitor Go6976 
and the inhibitor of MMP-2/ 9 reduced the amount 
of syndecan-4 present in the ECM (Figure 11B). 
To assess whether HS shedding may contribute to 
the increased TG2 activity found in the matrix 
following wounding (22,33), fluorescence staining 
using FITC-cadaverine as a measure of TG2 in 
situ activity was used. After wounding the tet-
inducible 3T3 cells in a scratch assay, cells were 
incubated for a 1 h period with FITC-cadaverine. 
As shown in Figure 12, the PKCα inhibitor 
Go6976, MMP-2/9 inhibitor, heparin and 
heparinase treatments and the peptidic TG2 
irreversible inhibitor R281 all reduced the 
presence of in situ TG2 activity found at the edge 
of the wound when compared to the non-treated 
control. This reduction was not seen with either 
MMP-8 or chondroitinase treatment, thus 
confirming the importance of syndecan shedding 
in delivering increased TG2 activity to the matrix 
after wounding. 
 
DISCUSSION 
Identifying and subsequently being able to 
regulate the mechanism of TG2 translocation into 
the ECM provides a novel strategy for modulating 
the pathological functions of the enzyme. Earlier 
studies suggest that cell surface HSPGs might be 
important in the trafficking of TG2 onto the cell 
surface (29). However, evidence for a HS binding 
site on TG2 has not been proven. We therefore 
identified the HS binding site(s) within TG2 by 
using a combination of amino acid sequence 
analysis for known HS-binding motifs and by 
analysis of the available crystal structures of TG2. 
Two potential binding sites were identified (HS1 
and HS2), which were docked with heparin 
derived oligosaccharides consisting of an iduronic 
acid-2-sulphate-glucosamine-2, 6-disulphate 
disaccharide, which is the most common repeating 
unit of heparin. Both the HS1 and HS2 sites 
docked well with all the oligosaccharides when 
TG2 was in its closed conformation although the 
HS2 site was the preferred site. In comparison, 
neither site docked well when the open 
conformation of TG2 was used, although slightly 
better docking was observed with the HS1 site. As 
a consequence, of these results it was decided to 
subject both sites to site directed mutagenesis of 
the key surface-exposed basic residues. By using a 
heparin affinity chromatography column we 
showed that the HS2 site, comprising residues 
202
KFLKNAGRDCSRRSSPVYVGR
222
, was 
required for high affinity binding to heparin 
whereas mutation of the HS1 site showed no 
difference in binding to that of the wt enzyme TG2 
can adopt two extremes of conformation: a 
compact conformation when guanine nucleotides 
are bound and an extended catalytically active 
conformation when guanine nucleotides  are 
displaced by calcium binding (33,34). Our docking 
studies for both the HS1 and HS2 site predicted a 
good interaction between the HS-binding site of 
the compact form of TG2 and heparin 
oligosaccharides, but the extended conformation in 
particular for the HS2 site did not produce 
comparable interactions, suggesting that binding 
affinities for TG2 and heparin might be 
conformation-dependent. Using heparin affinity 
chromatography, we confirmed that GTP-bound 
TG2 (compact form) binds strongly to heparin 
(eluted at 330mM NaCl), whereas R281-reacted 
TG2 (extended form) binds weaker (eluted at 
250mM NaCl). The C277S mutant, known to be in 
the extended conformation, binds to heparin with 
similar affinity to the R281-reacted TG2. Hence 
under normal physiological salt conditions the 
binding affinity of TG2 for cell surface HS is 
likely to be conformation dependent. 
Mutation of two surface exposed basic residues 
(K202 and R205) in the HS2 site did not affect 
TG2 activity or FN binding,  however this mutant 
only bound very weakly to the heparin column, 
with one large pool of mutant eluting at 60mM 
NaCl and another failing to bind at all. Both of 
these pools of eluted enzyme showed full TG 
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activity which could be inhibited by GTP 
indicating that the HS2 mutant is still able to bind 
to this nucleotide (Supplementary Figure 1). 
Hence the affinity of the K205, R209 mutant for 
heparin is significantly lower than that of either 
GTP-bound or R281-reacted wild type TG2 and it 
is likely that little binding would occur at 
physiological ionic strength. In support of this 
both HEK 293T/13 and NIH 3T3 cells expressing 
the HS2 mutant showed much reduced amounts of 
the HS2 mutant on the cell surface and it was 
found to be barely present in the ECM of the NIH 
3T3 cells. In view of a very recent paper (35) 
indicating that the N-terminal β-sandwich domain  
of TG2 is essential for TG2 secretion to the cell 
surface in kidney OK epithelial cells, we also 
measured the amount of the cell surface HS2 
mutant and matrix associated HS2 in these same 
cells (Supplementary Figure 3). Again despite a 
good expression level of this mutant, there was 
little HS2 mutant present at the cell surface, while 
the enzyme was absent in the matrix, thus agreeing 
with our data for the HEK and the HS2 mutant 
transfected NIH 3T3 cells. Support  for the 
importance of HS in the trafficking of TG2 to the 
cell surface was obtained using TG2 expressing 
HS-mutant CHO cells (which are unable to 
synthesize HS, but are still able to maintain the 
presence of the core proteins of the proteoglycans 
in the cell membrane (36)). A multiple alignment 
of TG peptide sequences, including TG2 from 
different species and human TG isoforms 
(Supplementary Figure 4) shows that the high 
affinity heparin binding domain is conserved 
amongst TG2 enzymes, but is absent from other 
isoforms with residues corresponding to human 
TG2 positions 202, 205, 213 and 222 conserved as 
basic residues amongst all the TG2 sequences 
analysed. 
Syndecan shedding is found in many physiological 
and pathological situations, where upregulation of 
TG2 expression also occurs e.g. during wound 
healing, in cancer migration and in bone 
differentiation and mineralisation (9,37). To study 
the involvement of syndecan shedding in the 
trafficking of TG2 into the matrix, we used the 
well characterised stably transfected Swiss 3T3 
cells, in which TG2 expression which results in 
easily detectable deposition of TG2 into the matrix 
is under the control of the tet-inducible promoter 
(13). Using both general and specific inhibitors of 
MMPs in these cells, we first demonstrated that 
MMP-2 and MMP-9, the two major MMPs 
involved in HS shedding (9,38,39), are required 
for the deposition of TG2 into the ECM. By 
protecting or inhibiting the cell surface HS from 
shedding by treating cells with heparin or the 
PKCα inhibitor Go6976, TG2 deposition into the 
matrix was reduced, while PMA, an accelerator 
for HS shedding, increased the amount of TG2 
deposited. Moreover, removal of the HS chains in 
the TG2 transfected tet-inducible 3T3 cells 
completely blocked the deposition of TG2 into the 
matrix. Parallel studies undertaken to measure the 
amount of syndecan-4 present in the cell matrix 
after treatment of cells with PMA, PKCα inhibitor 
Go6976 and the  inhibitor of MMP2/9 showed 
comparable levels of syndecan-4 in the matrix to 
that found for TG2 when treated with the same 
key modulators of syndecan shedding. 
Importantly, knocking down the expression of 
syndecan-4 expression in these 3T3 cells by 
siRNA significantly reduced the trafficking of 
TG2 into the ECM, further confirming the 
importance of syndecan-4 shedding in matrix TG2 
deposition. It is reported that wounding of cells or 
tissues results in a rapid but transient increase in 
the TG2 activity found in the matrix surrounding 
the wound area (22,33). We therefore looked to 
see if syndecan shedding may also account for this 
rapid increase in TG2 activity found around the 
wound area. Our data showed that the increased 
TG2 activity found around the wound area of 
TG2-inducible Swiss 3T3 cells could be either 
partially or totally blocked by agents known to 
affect syndecan shedding, thus supporting our 
claims for the importance of syndecan shedding in 
the trafficking of TG2 into the matrix following its 
increased expression in cells. Importantly this 
finding also fits with the suggested role of TG2 as 
a stress/wound  response  enzyme (40). 
It has been suggested that the mechanism of TG2 
secretion from cells may be dependent on 
conformation and its transition between the closed 
and open forms (3,41). Using this information and 
the data obtained for binding of the TG2 mutants 
to heparin and the importance of syndecan 
shedding in the trafficking of TG2 into the matrix, 
one might envisage a mechanism whereby TG2 is 
first externalised in its closed GTP-bound 
conformation. It is then retained at the cell surface 
by its high affinity binding to HS at physiological 
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ionic strength. Immediate binding to the 
negatively charged cell surface HS may also be 
responsible for maintaining the closed 
conformation of TG2 by sequestration of 
surrounding Ca
2+
 until the enzyme is translocated 
into the ECM via syndecan shedding. Once shed 
and exposed to Ca
2+
, TG2 will adopt an open 
conformation and the affinity for HS is 
significantly reduced, whereas its affinity for FN is 
increased (Supplementary Figure 5) enabling it 
to bind to and crosslink its matrix substrate 
proteins such as FN (42) (Figure 12). Subsequent 
oxidation or nitrosylation of the matrix bound 
enzyme then further modulates its transamidating 
activity (43,44), such that the enzyme may then 
act as a novel FN bound cell adhesion protein, 
either through its interaction with cell surface 
syndecan-4 or β integrins (19,45). 
Strong support for the role of TG2 as a novel cell 
adhesion protein working via interaction with 
syndecan-4 comes from the finding that the  
peptide representing the proposed binding pocket 
on TG2 for HS (P1 peptide) acted in a comparable 
manner  to TG2 in compensating RGD induced 
loss of cell adhesion when cells were plated onto 
FN, using a previously described osteoblast model 
(5). At concentrations as low as 5-10µg/ml, 
compensation of cell adhesion was noted. 
Moreover, when a α5β1 integrin blocking antibody 
was used to induce loss of cell adhesion, the P1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
peptide, like the full TG2 protein, was able to 
compensate the loss of adhesion, indicating the 
potency of this interaction and its ability to mimic 
TG2 (27). Fluorescence co-staining of F-actin and 
vinculin further demonstrated the ability of the P1 
peptide to restore loss of actin cytoskeleton 
organization and focal adhesion formation induced 
by the RGD peptide treatment. Importantly, this 
compensatory effect of the peptide could be 
abrogated by pre-treatment of cells with 
heparinase or treatment of cells with syndecan-4 
siRNA, indicating that P1 peptide like TG2 binds 
to cell surface syndecan-4. These data and the 
finding that the binding of the P1 peptide to 
syndecan-4 stimulates activation of PKCα, FAK at 
Tyr
397
 and subsequent activation of ERK1/2, 
confirm the importance of the interaction of TG2 
with cell surface syndecan-4 in its role as a cell 
adhesion protein.  
In summary, our findings with HS binding peptide 
and the discovery of a novel TG2 HS binding site 
confirm the importance of matrix bound TG2-
syndecan-4 interactions in cell adhesion. They also 
provide a new mechanism for the rapid 
translocation of TG2 into the ECM involving 
syndecan shedding. Moreover the demonstration 
of the potency of the HS binding peptide in 
modulating cell adhesion may also have future 
potential applications in regulating cell behaviour 
in TG2 mediated pathologies.
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FIGURE LEGENDS 
Figure 1. 3D structure of TG2 and predicted heparin binding site  (A) Surface 
representation of the crystal structure of TG2 (derived from 1KV3.pdb) with putative HSPG 
binding sites denoted by coloured shading. The position of the fibronectin binding site (FN) is 
also given. (B and C) Detailed view of the HS1 and HS2 sites, respectively, showing the 
juxtaposition of basic residues potentially involved in HSPG binding. (D and E) Predicted 
binding of a heparin-derived pentasaccharide into the HS1and HS2 sites, respectively, of 
TG2. Nitrogen atoms are coloured blue and oxygen atoms red. 
Figure 2. Expression and activity of TG2 and site directed TG2 mutants in HEK 
293/T17 and NIH 3T3 cells.  (A) Representative western blot showing expression levels of 
wt TG2 and TG2 mutants in HEK 293/T17 cells and (D) NIH 3T3 cells 48 h post-
transfection; (B, E) TG2 and mutant TG2  activity in cell lysates of HEK 293/T17 cells and 
NIH 3T3 cells; (C, F) TG2 and mutant expression levels were normalised to tubulin for equal 
loading. TG2 and mutant activity in cell lysates of HEK 293/T17 cells (C) and NIH 3T3 cells 
(F) are normalised for TG2 expression values obtained from Western blotting. Data shown in 
B-F are from 3 separate experiments. 
Figure 3. (A) Differences in the binding strength of TG2 mutants to heparin Sepharose. 
Cell lysates from HEK293/T17 cells transfected with TG2 and mutants were applied to a 
heparin Sepharose column (5ml) and eluted with a NaCl gradient as shown. Both flow-
through and resulting fractions (1-25 as shown) were assayed for TG2 by Western blotting 
with CUB7402. (B and C) The binding specificity of P1 peptide toward syndecan-4. (B) 
Solid binding assay was carried on to detect the binding between P1 peptide and recombinant 
human syndecan-4 or syndecan-2. The presence of the recombinant protein was detected by 
using anti-his tag antibody as described in the Experimental Procedures. (C) Representative 
Western blot performed with TG2 tetracycline-inducible Swiss 3T3 cells (tet-) to 
detect the presence of TG2 in the syndecan-4 immunocomplex in the presence of P1 
or P1s peptide as described in the Experimental Procedures.  
Figure 4. Effect of P1 peptide on the interaction between TG2 and syndecan-4 and the 
RGD-induced loss of cell adhesion on FN. (A) The compensatory effect of P1 peptide on 
loss of cell adhesion with the RGD peptide. HOB cells were treated with P1 peptide (0.01 to 
200μg/ml) with RAD or RGD peptides on FN. RAD-treated HOB cells were used as the 
control (the 0 group). Mean percentage value of the control attached and spread cells on FN ± 
S.D. (control) was set at 100%. (B) The effect of P1 peptide on the cell adhesion on TG-FN 
matrix.  FN or TG-FN matrix was prepared as introduced before and HOB cell adhesion 
assay was performed in the presence of P1 or P1s peptide (100-300µg/ml) on FN or TG-FN 
matrix as described the Experimental Procedures.  
Figure 5. (A) The co-staining of the actin cytoskeleton and vinculin of P1 or P1s-treated 
HOB cells on FN was undertaken as described in the Experimental Procedures. (B) Shows 
higher magnification of actin and vinculin staining in the presence of the P1 peptide and RGD 
with single cell image representing the co-localization of vinculin and actin. Arrows indicate 
presence of focal adhesion points.  
Figure 6.  Involvement of the cell surface α5β1 integrin and the importance of the HS 
chains of syndecan-4 in P1 peptide-regulated cell adhesion. (A)  The involvement of α5β1 
integrin. Cell attachment and spreading was performed in the presence of the α5β1 integrin 
blocking antibody (20µg/ml) and its isotype control antibody in the presence of P1 or P1s 
peptide on FN as described in the Experimental Procedures. (B) Importance of HS chains.  
HOB cells pre-treated with heparinase or chondroitinase (15mU/ml) were plated on FN with 
P1 or P1s peptide (100ug/ml) in the presence of RAD or RGD. Untreated HOB cells represent 
the control group (CNTL) as described in the Experimental Procedures. Mean percentage 
value of the control attached and spread cells on FN ± S.D. was set at 100%.  
Figure 7. The involvement of syndecan-4 and its downstream signalling molecule PKCα 
in the P1 peptide mediated RGD-independent cell adhesion. (A) Requirement of 
syndecan-4 by the P1 peptide. Cell adhesion assays using HOB cells treated with syndecan-
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4 targeting or NS siRNA on FN in the presence of P1 or P1s control peptide (100ug/ml) was 
performed as introduced in the Experimental Procedures. Mean percentage value of the 
control attached and spread cells on FN±S.D. was set at 100%.  (B and C) The importance 
of PKCα in P1 peptide-mediated cell adhesion. Cell attachment and spreading of HOB 
cells on FN with RGD or RAD was performed using PKCα inhibitor Go6976 or the GK21 
peptide- in the presence of 100ug/ml P1 or P1s peptide as described in the Experimental 
Procedures. Mean percentage value of the DMSO-treated attached and spread control cells on 
FN ± S.D. (control) was set at 100%.   
Figure 8. Identification of the intracellular signalling molecules in P1 peptide-mediated 
signalling transduction. (A-D) Phosphorylation of FAK and ERK1/2 in P1 peptide-
mediated signalling transduction. HOB cell adhesion was undertaken with the P1 or P1s 
peptides (100ug/ml) as described in the Experimental Procedures. P-FAK
397
 (A) and p-
ERK1/2 (C) were detected by Western blotting. Membranes were reprobed to detect the total 
FAK or ERK1/2, while α-tubulin was used as the standard for equal loading. Relative 
amounts of p-397 FAK (B) and p-ERK1/2 (D) compared to total FAK or ERK1/2 was 
measured by densitometry and normalised to tubulin and then represented as a percentage of 
that calculated for FN in the presence of RAD. Values are shown as the mean ± S.D. from 3 
separate experiments. (E-G). Affinity of TG2 and the binding site mutant (D94A, D97A), 
the N-terminal deletion product of TG2 (Δ1-15) and the HS2 mutant (K205A, R209A) 
for binding to FN. (E) Clarified cell lysates (60μg protein) from transiently transfected cells 
were added to FN-coated plates and the TG2 proteins detected as described in the Materials 
and Methods. Data shown are normalised for expression of TG2 and its mutants in the 
different cell lysates using densitometry values from Western blots after normalisation to 
tubulin. The values represent mean values ± SD from 3 experiments. (F and G) Human 
recombinant TG2 (2μg/ml) was added to microtitre plates previously coated with FN, or the 
N-terminal 70kDa or 45kDa FN fragments. Prior to addition of the TG2, wells were blocked, 
washed and then incubated with either the P2 peptide (F) or the scrambled P2 peptide (G, 
P2s) as described in the Materials and Methods. Data show the mean values ± S.D. from 3 
experiments. 
Figure 9.  (A and B) Detection of extracellular TG2 in NIH 3T3 cells transfected with 
wild type TG2 and TG2 mutants and (C-D) presence of extracellular TG2 in CHO K1 
cells and the HS deficient CHO-K1 derivative pgsD-677. (A)Cell surface TG2 and mutants 
were detected by Western blotting after treatment of cells with sulfo-NHS-LC-biotin. 
Densitometry values (mean value from 2 experiments) for the different TGs are from Western 
blots normalised for loading and TG2 expression levels as described in Figure 2. (B) For 
TG2 and TG2 mutants in the ECM, transfected NIH 3T3 cells were grown for 24 h post 
transfection in full DMEM medium and for a further 24 h in 1% serum. TG2 antigen in the 
ECM was detected by Western blotting with Cub7402. The bars in the  histogram represents 
the mean values for matrix TG2 and its mutants as a percentage of the wt TG2 after 
normalising for the relative expression of TG2 in the cell lysates. Taken from two 
independent experiments as described in the Experimental Procedures. (C) Cell surface TG2 
in CHO cells and its HS deficient CHO-K1 derivative was detected after treatment of cells 
with sulfo-NHS-LC-biotin as described above.  (D) Relative amounts of cell surface TG2 
expressed as a percentage of the wt CHO cells measured by densitometry of the Western blots 
(mean values from 2 experiments) after normalising to the expression of TG2 as describe in 
(A) above.  
Figure 10. HS shedding and its effects on the trafficking of TG2 into the ECM. General 
MMP inhibitor GM6001 (GM) (A) or specific MMP inhibitors for MMP-2/ 9, MMP-3 and 
MMP-8 (10µM) (B) were used to treat the TG2 induced (tet-) and non-induced (tet+) 3T3 
cells. Cell lysates and matrix fractions after 48 h were western blotted to detect TG2 antigen 
in the fractions. The bars in the histogram represents the mean values for matrix TG2 
represented as a percentage of the non treated control cells  after normalising for the relative 
expression of TG2 in the cell lysates. Taken from two independent experiments as described 
in the Experimental Procedures.  (C) The effect of HS on TG2 deposition. Cell lysates and 
matrix fractions from tet-inducible 3T3 cells induced (tet-) or not induced (tet+) for TG2 were 
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incubated with PMA (50nM), PKCα inhibitor Go6976 (Go) (5µM), heparin (HN) (10µg/ml), 
heparinase (HNase) or chondroitinase (CD) (15mU/ml) were used in Western blotting to 
detect TG2 and levels (mean of two experiments) expressed as a percentage of the non treated 
control, calculated as described in (B) above. 
Figure 11. (A) Role of syndecan-4 in TG2 deposition into the ECM. Syndecan-4 siRNAs 
were used to silence syndecan-4 expression in TG2 transfected tet-inducible 3T3 cells prior to 
detection of TG2 deposition into the ECM in TG2 induced (tet+) and non-induced (tet-) by 
western blotting. The bars in the  histogram represents the mean values for matrix TG2 
represented as a percentage of the NS  treated control cells  after normalising for the relative 
expression of TG2 in the cell lysates. Taken from two independent experiments as described 
in the Experimental Procedures. (B) The presence of shed syndecan-4 in ECM. 
Representative dot blot  applied to detect the presence of syndecan-4 in the ECM fractions in 
TG2 transfected tet-inducible 3T3 cells after treatment with PMA(50nM), PKCα inhibitor 
Go6976(5µM) and MMP-2/9 inhibitor(10µM), using a specific antibody against the 
ectodomain of syndecan-4 to detected the syndecan-4 as described in the Experimental 
Procedures. The histogram represents the mean densitometric values from 2 independent 
experiments.  
Figure 12.  The effect of HS in wound –induced TG2 deposition. In situ activity of TG2 in 
TG2 transfected tet-inducible (tet-) 3T3 cells seeded into 8-well chambers detected by 
incorporation of FITC-cadaverine after different treatments was visualized using fluorescence 
microscopy as described in the Experimental Procedures. The dotted line marks the edge 
between the cell area (marked C in the image) and the wound areas (marked W).  
Figure 13. Schematic representation of a potential mechanism for translocation of TG2 
into the extracellular matrix. Cell surface TG2 in its compact conformation bound to cell 
surface syndecan-4 is deposited into the ECM by syndecan shedding. This process is 
regulated by intracellular signalling molecule PKCα, an activator of syndecan-4 shedding. 
Once shed from the cell surface TG2 takes on its open conformation following increased 
exposure to Ca
2+
 facilitating both FN binding and matrix deposition and activation of protein 
crosslinking. 
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Table 1. Antibodies used in this study 
 
Antigen Host species Clone Company 
TG2 Mouse Monoclonal Thermo Fisher 
p-FAK397 Mouse Monoclonal Millipore 
Total FAK Rabbit Polyclonal Santa Cruz 
p-ERK1/2 Rabbit Polyclonal Santa Cruz 
Total ERK1/2 Rabbit Polyclonal Santa Cruz 
Syndecan-4 Rabbit Polyclonal Invitrogen 
Syndecan-4 ectodomain Goat Polyclonal Santa Cruz 
Syndecan-2 Rabbit Polyclonal Invitrogen 
β1 Integrin Rabbit Polyclonal Santa Cruz 
α-Tubulin Mouse Monoclonal Sigma-Aldrich 
Vinculin Mouse Monoclonal Sigma-Aldrich 
6× His tag Mouse  Monoclonal Invitrogen 
α5β1 integrin blocking 
antibody and Isotype 
control antibody 
Mouse Monoclonal Biolegend 
HRP-conjugated anti-
mouse secondary 
Rabbit  Sigma 
HRP-conjugated anti-
rabbit secondary 
Swine  Dako 
TRITC-conjugated anti-
mouse secondary 
Rabbit  Dako 
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Table 2. Primers used in this study 
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